KRVS

Rob Stein

Rob Stein is a correspondent and senior editor on NPR's science desk.

An award-winning science journalist with more than 25 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues and other science, medical, and health policy news.

Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.

Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.

Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science and the Association of Health Care Journalists.

Many healthy Americans take a baby aspirin every day to reduce their risk of having a heart attack, getting cancer and even possibly dementia. But is itreally a good idea?

Results released Sunday from a major study of low-dose aspirin contain a disappointing answer for older, otherwise healthy people.

It's early in the morning and 20-year-old Aaron Reid looks like he's sleepwalking.

His head nods forward and he shuffles a bit as he heads toward the pediatric clinic at the National Institutes of Health Clinical Center.

Reid, who has been fighting leukemia since he was 9-years old, is experiencing intense pain.

He can't say much at the moment, so his mother, Tracie Glascox, speaks for him. "He's been complaining of pain in his ankles, his knees and his arms," she tells the nurse.

The Food and Drug Administration announced a set of major new enforcement actions Wednesday aimed at reducing the sales and marketing of electronic cigarettes to teenagers.

Saying vaping among teenagers has reached "an epidemic proportion," the agency said it was taking a "series of critical and historic" measures to curb the alarming trends.

Editor's note: Story updated with additional information about generic pricing on August 17.

The Food and Drug Administration has approved the first identical alternative to the EpiPen, which is widely used to save children and adults suffering from dangerous allergic reactions.

The FDA Thursday authorized Teva Pharmaceuticals USA to sell generic versions of the EpiPen and EpiPen Jr for adults and children who weigh more than 33 pounds.

Aaron Reid is lying in a hospital bed at the National Institutes of Health Clinical Center when doctors arrive to make sure he's ready for his experimental treatment.

"How's your night? Any issues?" asks Dr. Katherine Barnett, a pediatric oncologist, as they begin to examine Reid.

Reid, 20, of Lucedale, Miss., has been fighting leukemia since he was 9 years old. He has been through chemotherapy and radiation twice, a bone marrow transplant and two other treatments.

Pages